序号 |
标题 |
次数 |
作者 |
发布时间 |
74206 |
cas:2129164-91-4 , DBCO-PEG4-Val-Cit-PAB-MMAE,二苯并环辛炔-四聚乙二醇-VAL-CIT-PAB-MMAE |
152 |
kx |
2024-12-19 |
74207 |
MAL-di-EG-Val-Cit-PAB-MMAF,由ADC连接桥(MAL-di-EG-Val-Cit-PAB)和有效的微管蛋白聚合阻断剂(MMAF, Monomethyl auristatin F)组成 |
116 |
WYQ |
2024-12-19 |
74208 |
MAL-di-EG-Val-Cit-PAB-MMAE,CAS编号:2746391-62-6 |
126 |
WYQ |
2024-12-19 |
74209 |
cas:644981-35-1 , Val-Cit-PAB-MMAE, ADC试剂 |
75 |
kx |
2024-12-19 |
74210 |
cas:2754384-60-4,DBCO-(PEG)3-VC-PAB-MMAE,抗体药物偶联物(ADC) |
151 |
kx |
2024-12-19 |
74211 |
AcLys-PABC-VC-Aur0101(CAS:1438851-17-2) |
107 |
WYQ |
2024-12-19 |
74212 |
反式环辛烯-MMAE,TCO-MMAE, ADC试剂 |
133 |
kx |
2024-12-19 |
74213 |
Hydrazone-doxorubicin,阿霉素-腙键偶联物 |
173 |
WYQ |
2024-12-19 |
74214 |
SPP-DM1(CAS号:452072-20-7)C44H59ClN4O14S2 |
142 |
WYQ |
2024-12-19 |
74215 |
氨基-二聚乙二醇-VG-N-双(一聚乙二醇-叠氮),Amino-PEG2-VG-N-Bis(PEG1-azide) |
68 |
kx |
2024-12-19 |
74216 |
DOTA-NHS ester,羟基琥珀酰亚胺-四氮杂环十二烷四乙酸(CAS号:170908-81-3) |
95 |
WYQ |
2024-12-19 |
74217 |
Maleimido-mono-amide-DOTA(CAS号:1006711-90-5) |
152 |
WYQ |
2024-12-19 |
74218 |
cas:2055041-40-0,Azido-PEG1-Val-Cit-PAB-OH,叠氮-一聚乙二醇-VAL-CIT-PAB-羟基 |
69 |
kx |
2024-12-19 |
74219 |
MB-VC-MGBA CAS号:932744-62-2 |
106 |
WYQ |
2024-12-19 |
74220 |
Anti-GPNMB-VC-MMAE-ADC抗体偶联药物 |
86 |
zyl |
2024-12-19 |
74221 |
MA-PEG8-VA-PAB-SG3199,硫醇反应SET™毒素 |
137 |
WYQ |
2024-12-19 |
74222 |
cas:1662687-83-3 , Mal-PEG2-Val-Cit-PABA,马来酰亚胺-二聚乙二醇-VAL-CIT-PABA |
78 |
kx |
2024-12-19 |
74223 |
Boc-Val-Ala-PAB cas:1884577-99-4 |
82 |
zyl |
2024-12-19 |
74224 |
perfluorophenyl 1-(cyclooct-2-ynyloxy)-2-oxo-6,9,12-trioxa-3-azapentadecan-15-oate |
71 |
wyh |
2024-12-19 |
74225 |
MA-PEG4-VA-PBD(CAS号:2259318-50-6) |
102 |
WYQ |
2024-12-19 |
74226 |
SPDP-Val-Cit-PAB-PNP-ADC抗体偶联药物 |
136 |
zyl |
2024-12-19 |
74227 |
cas:1438853-35-0,Mal-PEG3-Val-Cit-PAB-PNP,马来酰亚胺-三聚乙二醇-VAL-CIT-PAB-PNP 酯 |
71 |
kx |
2024-12-19 |
74228 |
Mc-vc-PABC-SP 141,一种用于抗体药物偶联物(ADC)合成的linker或连接臂 |
75 |
WYQ |
2024-12-19 |
74229 |
perfluorophenyl 1-(1,3-dioxoisoindolin-2-yloxy)-3,6,9,12-tetraoxapentadecan-15-oate |
104 |
wyh |
2024-12-19 |
74230 |
cas:2055041-37-5,Mal-PEG1-Val-Cit-PAB-OH,马来酰亚胺-一聚乙二醇-VAL-CIT-PAB-羟基 |
107 |
kx |
2024-12-19 |
74231 |
perfluorophenyl 15-(2,5-dioxo-2H-pyrrol-1(5H)-yl)-13-oxo-3,6,9-trioxa-12-azapentadecan-1-oate |
92 |
wyh |
2024-12-19 |
74232 |
MC-Val-Cit-PAB-PNP cas:159857-81-5 |
91 |
zyl |
2024-12-19 |
74233 |
NAMPT-linker(CAS号:2241019-57-6) |
77 |
WYQ |
2024-12-19 |
74234 |
cas:103848-61-9,6-Maleimidocaproic acid sulfo-NHS |
92 |
wyh |
2024-12-19 |
74235 |
cas:159857-80-4 ,MC-Val-Cit-PAB-OH, ADC(抗体偶联药物 ) |
99 |
kx |
2024-12-19 |
74236 |
Boc-Val-Cit cas:870487-08-4 |
125 |
zyl |
2024-12-19 |
74237 |
cas:663598-66-1,1-((4-((5-Nitropyridin-2-yl)disulfanyl)pentanoyl)oxy)-2,5-dioxopyrrolidine-3-sulfonic acid |
84 |
wyh |
2024-12-19 |
74238 |
cas:870487-10-8,Boc-Val-Cit-PAB-PNP,BOC-VAL-CIT-PAB-PNP 酯 |
88 |
kx |
2024-12-19 |
74239 |
cas:2353409-69-3 Mal-PEG8-Val-Cit-PAB-MMAE |
133 |
zyl |
2024-12-19 |
74240 |
cas:108852-90-0 Nemorubicin 奈莫柔比星 |
109 |
zyl |
2024-12-19 |
74241 |
cas:159858-22-7 , Fmoc-Val-Cit-PAB-OH,ADC(抗体偶联药物) |
72 |
kx |
2024-12-19 |
74242 |
cas:1626359-59-8 磺基-SPDB-DM4 |
80 |
zyl |
2024-12-19 |
74243 |
cas:870487-09-5,Boc-Val-Cit-PAB, ADC试剂 |
72 |
kx |
2024-12-19 |
74244 |
NH2-Glu-Gly-Cit-PAB-OH, ADC试剂 |
141 |
kx |
2024-12-19 |
74245 |
sulfo-SPDB-DGN462,用于提高化合物的水溶性和稳定性 |
128 |
WYQ |
2024-12-19 |
74246 |
Fmoc-Gly-Gly-Phe-Gly-OH, ADC试剂 |
104 |
kx |
2024-12-19 |
74247 |
1342211-31-7,MC-Val-Ala-OH,马来酰亚胺基己酰-L-缬氨酰-L-丙氨酸,ADC连接子多肽 |
131 |
kx |
2024-12-19 |
74248 |
MA-PEG4-VC-PAB-DMAE-PNU159682(CAS号:2259318-52-8) |
98 |
WYQ |
2024-12-19 |
74249 |
MC-vc-PAB-C6-a-amanitin,一种抗体药物偶联物(ADC) |
95 |
WYQ |
2024-12-19 |
74250 |
cas:690632-55-4,N-Succinimidyloxycarbonylpropyl Methanethiosulfonate |
62 |
wyh |
2024-12-19 |